CO2018005491A2 - Formulación de combinación de dosis fija, eflornitina y sulindaco - Google Patents
Formulación de combinación de dosis fija, eflornitina y sulindacoInfo
- Publication number
- CO2018005491A2 CO2018005491A2 CONC2018/0005491A CO2018005491A CO2018005491A2 CO 2018005491 A2 CO2018005491 A2 CO 2018005491A2 CO 2018005491 A CO2018005491 A CO 2018005491A CO 2018005491 A2 CO2018005491 A2 CO 2018005491A2
- Authority
- CO
- Colombia
- Prior art keywords
- eflornithine
- sulindac
- fixed dose
- formulation
- dose combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248810P | 2015-10-30 | 2015-10-30 | |
| US201662358698P | 2016-07-06 | 2016-07-06 | |
| EP16306430 | 2016-10-28 | ||
| EP16306429 | 2016-10-28 | ||
| PCT/US2016/059689 WO2017075576A1 (en) | 2015-10-30 | 2016-10-31 | Eflornithine and sulindac, fixed dose combination formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018005491A2 true CO2018005491A2 (es) | 2018-06-12 |
Family
ID=57256487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0005491A CO2018005491A2 (es) | 2015-10-30 | 2018-05-25 | Formulación de combinación de dosis fija, eflornitina y sulindaco |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10973790B2 (enExample) |
| EP (1) | EP3368029B1 (enExample) |
| JP (3) | JP2018536707A (enExample) |
| KR (3) | KR20180069068A (enExample) |
| CN (1) | CN108366982A (enExample) |
| AU (1) | AU2016343851B2 (enExample) |
| BR (1) | BR112018008651A2 (enExample) |
| CA (1) | CA3003149C (enExample) |
| CL (1) | CL2018001157A1 (enExample) |
| CO (1) | CO2018005491A2 (enExample) |
| HK (1) | HK1258284A1 (enExample) |
| IL (1) | IL259009A (enExample) |
| MA (1) | MA43114A (enExample) |
| MX (1) | MX390899B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018536707A (ja) | 2015-10-30 | 2018-12-13 | キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド | エフロルニチンとスリンダクの固定用量複合製剤 |
| NZ792518A (en) | 2016-10-06 | 2023-04-28 | Orbus Therapeutics Inc | Formulations for administration of eflornithine |
| TWI917322B (zh) | 2019-05-17 | 2026-03-11 | 美商癌症預防製藥股份有限公司 | 治療家族性腺瘤性瘜肉症之方法 |
| US12605349B2 (en) | 2024-09-05 | 2026-04-21 | Orbus Therapeutics, Inc. | Methods of treating grade 3 astrocytoma |
| CN119909027B (zh) * | 2025-01-21 | 2025-11-18 | 福安药业集团宁波天衡制药有限公司 | 一种稳定的舒林酸片及其制备方法 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309442A (en) * | 1977-07-11 | 1982-01-05 | Merrell Toraude Et Compagnie | Method for controlling fertility in mammals |
| US4330559A (en) | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| US4499072A (en) | 1982-11-29 | 1985-02-12 | Merrell Dow Pharmaceuticals Inc. | Process for treating diseases with ODC inhibitors |
| US4859452A (en) | 1986-01-17 | 1989-08-22 | Board Of Regents, The University Of Texas System | Methods for the reduction of difluoromethylornithine associated toxicity |
| US4925835A (en) | 1986-05-01 | 1990-05-15 | Sloan-Kettering Institute For Cancer Research | Aziridinyl putrescine containing compositions and their uses in treating prostate cancer |
| US5002879A (en) | 1986-05-06 | 1991-03-26 | Merrell Dow Pharmaceuticals | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor |
| FR2706255B1 (fr) | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| EP0886519A1 (en) * | 1996-11-01 | 1998-12-30 | Ilex Oncology, Inc. | Sustained release formulation containing dfmo |
| US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| EP1067919A1 (en) | 1998-03-28 | 2001-01-17 | THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA | Dfmo and sulindac combination in cancer chemoprevention |
| US7700568B2 (en) | 1998-06-30 | 2010-04-20 | Sloan-Kettering Institute For Cancer Research | Uses of DNA-PK |
| WO2000038715A2 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of an integrin antagonist and radiation in the treatment of neoplasia |
| US20050037090A1 (en) | 1998-12-23 | 2005-02-17 | Mckearn John P. | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent |
| US6753422B2 (en) | 1999-03-01 | 2004-06-22 | O'brien Thomas G. | Odc allelic analysis method for assessing carcinogenic susceptibility |
| CA2373931A1 (en) | 1999-05-17 | 2000-11-23 | Richard Love | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
| WO2001068076A2 (en) | 2000-03-07 | 2001-09-20 | Ilex Oncology, Inc. | D-enantiomer of dfmo and methods of use thereof for treating cancer |
| US6602910B2 (en) | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
| AU2001285232A1 (en) | 2000-08-24 | 2002-03-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| GB0125492D0 (en) | 2001-10-24 | 2001-12-12 | Astrazeneca Ab | Formulation |
| AU2002343609B2 (en) | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| EP1575584A4 (en) * | 2002-11-29 | 2006-02-01 | Forest Laboratories | METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON |
| US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| WO2007012019A2 (en) * | 2005-07-18 | 2007-01-25 | Horizon Therapeutics, Inc. | Medicaments containing famotidine and ibuprofen and administration of same |
| WO2007075673A1 (en) | 2005-12-20 | 2007-07-05 | University Of Hawaii | Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors |
| DK2043637T3 (da) * | 2006-07-18 | 2012-05-07 | Horizon Pharma Usa Inc | Fremgangsmåder og medikamenter til administrering af ibuprofen |
| AR067557A1 (es) * | 2007-07-19 | 2009-10-14 | Takeda Pharmaceutical | Preparacion solida y metodo de preparacion |
| CA2694389C (en) | 2007-08-01 | 2016-01-19 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A | Treatment of pediatric tumors |
| WO2009022670A1 (ja) * | 2007-08-10 | 2009-02-19 | Takeda Pharmaceutical Company Limited | 速崩壊性錠剤 |
| US8283331B2 (en) | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| WO2009052518A2 (en) * | 2007-10-19 | 2009-04-23 | Aspen Benefits Group, Llc | Methods and compositions directed to reduction of facial hair hirsutism in females |
| CA2753844A1 (en) | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
| US20100120727A1 (en) | 2008-11-12 | 2010-05-13 | Kyphia Pharmaceuticals, Inc. | Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof |
| MX2011005731A (es) | 2008-12-08 | 2011-06-21 | Procter & Gamble | Composicion para el ciudado personal en la forma de un articulo que tiene un recubrimiento hidrofobo residente en la superficie. |
| DK2430452T3 (da) | 2009-05-14 | 2014-10-06 | Univ Arizona State | Carcinom-diagnose og behandlinger, baseret på odc1-genotype |
| SG176096A1 (en) | 2009-05-20 | 2011-12-29 | Ranbaxy Lab Ltd | Liquid dosage forms of isotretinoin |
| CN101898978A (zh) | 2009-05-31 | 2010-12-01 | 徐锋 | 依氟鸟氨酸前药和偶合物及其使用方法 |
| US20110256161A1 (en) | 2010-04-19 | 2011-10-20 | Aminex Therapeutics Inc. | Methods for enhancing immune response |
| EP2563936B1 (en) | 2010-04-29 | 2018-03-14 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| EP2568978B1 (en) | 2010-05-14 | 2019-04-24 | Arizona Board of Regents on Behalf of University of Arizona | Cancer prevention and treatment based on dietary polyamine content |
| US8853423B2 (en) * | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| NZ603581A (en) | 2010-06-19 | 2015-05-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
| EP2912193B1 (en) | 2012-10-29 | 2018-08-29 | Arizona Board of Regents on Behalf of University of Arizona | Predictive markers for polyamine inhibitor cancer therapies |
| GB2513299A (en) | 2013-03-12 | 2014-10-29 | Cellact Pharma Gmbh Biomedizinzentrum | Compounds for targeting cancer stem cells |
| LT3421033T (lt) * | 2013-10-07 | 2022-11-10 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Atazanaviro ir kobicistato kompozicija, skirta živ gydymui |
| KR20150079373A (ko) * | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| CA2952771A1 (en) | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| JP2018507910A (ja) | 2015-02-12 | 2018-03-22 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ | 神経芽細胞腫を治療する方法 |
| WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
| JP2018536707A (ja) | 2015-10-30 | 2018-12-13 | キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド | エフロルニチンとスリンダクの固定用量複合製剤 |
-
2016
- 2016-10-31 JP JP2018543001A patent/JP2018536707A/ja not_active Withdrawn
- 2016-10-31 KR KR1020187015233A patent/KR20180069068A/ko not_active Ceased
- 2016-10-31 CN CN201680071715.3A patent/CN108366982A/zh active Pending
- 2016-10-31 KR KR1020247034905A patent/KR20240162560A/ko not_active Ceased
- 2016-10-31 MA MA043114A patent/MA43114A/fr unknown
- 2016-10-31 KR KR1020267006230A patent/KR20260033630A/ko active Pending
- 2016-10-31 US US15/771,484 patent/US10973790B2/en active Active
- 2016-10-31 BR BR112018008651-7A patent/BR112018008651A2/en not_active IP Right Cessation
- 2016-10-31 HK HK19100648.5A patent/HK1258284A1/zh unknown
- 2016-10-31 EP EP16794183.0A patent/EP3368029B1/en active Active
- 2016-10-31 AU AU2016343851A patent/AU2016343851B2/en active Active
- 2016-10-31 MX MX2018005350A patent/MX390899B/es unknown
- 2016-10-31 CA CA3003149A patent/CA3003149C/en active Active
-
2018
- 2018-04-29 IL IL259009A patent/IL259009A/en unknown
- 2018-04-30 CL CL2018001157A patent/CL2018001157A1/es unknown
- 2018-05-25 CO CONC2018/0005491A patent/CO2018005491A2/es unknown
-
2021
- 2021-03-05 US US17/193,588 patent/US11529326B2/en active Active
- 2021-11-17 JP JP2021186911A patent/JP7592001B2/ja active Active
-
2022
- 2022-11-15 US US18/055,494 patent/US11925613B2/en active Active
-
2024
- 2024-02-07 US US18/435,678 patent/US12350246B2/en active Active
- 2024-05-15 JP JP2024079276A patent/JP2024102339A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3368029C0 (en) | 2026-05-27 |
| EP3368029A1 (en) | 2018-09-05 |
| MA43114A (fr) | 2018-09-05 |
| US20230172887A1 (en) | 2023-06-08 |
| MX390899B (es) | 2025-03-21 |
| MX2018005350A (es) | 2018-08-14 |
| CA3003149A1 (en) | 2017-05-04 |
| US20240173284A1 (en) | 2024-05-30 |
| JP7592001B2 (ja) | 2024-11-29 |
| AU2016343851B2 (en) | 2022-04-07 |
| IL259009A (en) | 2018-07-31 |
| US11925613B2 (en) | 2024-03-12 |
| EP3368029B1 (en) | 2026-05-27 |
| KR20180069068A (ko) | 2018-06-22 |
| CN108366982A (zh) | 2018-08-03 |
| CL2018001157A1 (es) | 2018-09-07 |
| US20200009098A1 (en) | 2020-01-09 |
| US10973790B2 (en) | 2021-04-13 |
| BR112018008651A2 (en) | 2018-10-30 |
| KR20260033630A (ko) | 2026-03-10 |
| JP2024102339A (ja) | 2024-07-30 |
| KR20240162560A (ko) | 2024-11-15 |
| HK1258284A1 (zh) | 2019-11-08 |
| JP2018536707A (ja) | 2018-12-13 |
| US12350246B2 (en) | 2025-07-08 |
| JP2022028814A (ja) | 2022-02-16 |
| CA3003149C (en) | 2023-10-31 |
| AU2016343851A1 (en) | 2018-05-10 |
| US11529326B2 (en) | 2022-12-20 |
| US20210267926A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| EP3490539A4 (en) | NEW ORAL FORMULATION. | |
| NZ747040A (en) | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride | |
| MX2017014809A (es) | Amidas heterociclicas como inhibidores de cinasa. | |
| BR112016020199A2 (pt) | Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| BR112015023417A2 (pt) | compostos heterocíclicos e seus usos | |
| BR112016025910A2 (pt) | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos | |
| EP4233846C0 (en) | PHARMACEUTICAL FORMULATIONS | |
| DK3684333T3 (da) | Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| MX361327B (es) | Combinaciones de alquilamidotiazoles y sustancias de filtro uv. | |
| PE20180528A1 (es) | Composiciones de plinabulina | |
| CL2017001964A1 (es) | Encapsulado de agentes activos de alta potencia. | |
| MX2019014772A (es) | Formulaciones en gel de bisfosfocinas y usos de estas. | |
| UY35424A (es) | Xantinas sustituidas y métodos para su uso | |
| MX2016017025A (es) | Formulaciones de proteinas. | |
| MX2018005350A (es) | Formulacion de combinacion de dosis fija, eflornitina y sulindaco. | |
| CO2017007316A2 (es) | Formulación farmacéutica | |
| DK4233850T3 (da) | Kapselformuleringer | |
| MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
| CR20150145A (es) | Composiciones con matriz de resina fundida en caliente | |
| EP3630113A4 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR | |
| MX394089B (es) | Nuevos derivados de xantina sustituidos. | |
| EP3746080A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| DK3411008T3 (da) | Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren |